Lilly Zyprexa Patent Challenge Summary Judgment Motions Expected In June
Executive Summary
Lilly expects to initiate summary judgment motions in June in consolidated patent litigation related to its antipsychotic Zyprexa, Senior VP & General Counsel Bob Armitage told investors in New York April 4